Immune checkpoint inhibitors play a crucial role in the treatment of lung cancer that lacks driver mutations, while the presence of PD-L1 on tumor cells serves as an indicator of the effectiveness of anti-PD-1/PD-L1 treatments. This evidence concerns the gene PDCD1 and lung cancer.